Aristan

(saracatinib)

Phase 2Small molecule

Saracatinib is being investigated for treating certain cancers and bone diseases, particularly osteoporosis and metastatic bone disease, by blocking proteins that help cancer cells grow and survive.[1] Aristan is currently being investigated across 22 indications[3], with its most advanced program in Phase 2.[1]

Aristan is one of 540 small molecule programs targeting Thymus Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

539

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thymus NeoplasmActive, not recruiting

OsteosarcomaActive, not recruiting

Bone PainActive, not recruiting

ThymomaActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Malignant Colon NeoplasmActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

PsychosisActive, not recruiting

Colorectal AdenocarcinomaActive, not recruiting

Alcohol DependenceActive, not recruiting

Thymus NeoplasmPhase 2

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Bone PainPhase 2

Active, not recruiting

ThymomaPhase 2

Active, not recruiting

Alzheimer DiseasePhase 2

Active, not recruiting

Malignant Colon NeoplasmPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

PsychosisPhase 1

Active, not recruiting

Colorectal AdenocarcinomaPhase 2

Active, not recruiting

Alcohol DependencePhase 1

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Aristan

NNational Cancer Institute (NCI)

Phase 2

1 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Voltaren

Novartis

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Acupan

YYonsei University

Preclinical

1 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphangioleiomyomatosis2 trials

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Terminated·—·Phase 2·NCT02737202·28 enrolled

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Completed·TTony Eissa·Phase 1·NCT02116712·9 enrolled

Prostate Cancer2 trials

Saracatinib in Treating Patients With Prostate Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01267266·31 enrolled

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00513071·28 enrolled

Metastatic Head and Neck Cancer1 trial

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00513435·9 enrolled

Small Cell Lung Cancer1 trial

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00528645·23 enrolled

Ovarian Cancer1 trial

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Completed·UUniversity College, London·Phase 2/3·NCT01196741·107 enrolled

14 more indications

Osteosarcoma1 trial

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Terminated·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00752206·38 enrolled

Pancreatic Cancer1 trial

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00735917·19 enrolled

Bone pain1 trial

SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 2·NCT02085603·12 enrolled

Alzheimer's Disease1 trial

Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease

Completed·—·Phase 1·NCT01864655·24 enrolled

Melanoma1 trial

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00669019·23 enrolled

Breast Cancer1 trial

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00559507·12 enrolled

Soft Tissue Sarcoma1 trial

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00659360·17 enrolled

Gastroesophageal Junction Cancer1 trial

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00607594·21 enrolled

Chemotherapy1 trial

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00638937·37 enrolled

Interaction1 trial

Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers

Completed·YYale University·Phase 1·NCT02732587·5 enrolled

Alcohol Drinking1 trial

Saracatinib and Alcohol Drinking

Completed·YYale University·Phase 2·NCT02955186·50 enrolled

Psychosis1 trial

SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

Unknown status·KKing's College London·Phase 1·NCT03661125·30 enrolled

Thymoma1 trial

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00718809·21 enrolled

Metastatic Colon Cancer1 trial

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00397878·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for saracatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — saracatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for saracatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tyrosine-Protein Kinase ABL Inhibitor; Tyrosine-Protein Kinase SRC Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Aristan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphangioleiomyomatosis2 trials

Prostate Cancer2 trials

Metastatic Head and Neck Cancer1 trial

Small Cell Lung Cancer1 trial

Ovarian Cancer1 trial

Osteosarcoma1 trial

Pancreatic Cancer1 trial

Bone pain1 trial

Alzheimer's Disease1 trial

Melanoma1 trial

Breast Cancer1 trial

Soft Tissue Sarcoma1 trial

Gastroesophageal Junction Cancer1 trial

Chemotherapy1 trial

Interaction1 trial

Alcohol Drinking1 trial

Psychosis1 trial

Thymoma1 trial

Metastatic Colon Cancer1 trial

References

Drug Info

Quick Facts

Related News